Bone marrow derived extracellular vesicles activate osteoclast differentiation in traumatic brain injury induced bone loss

Quante Singleton¹, Kumar Vaibhav², Molly Braun², Andrew Khayrullin³, Bharati Mendhe³, Ravindra Kolhe⁴, Helen Kaiser³, Mohamed E. Awad⁵, Tunde Fariyike², Ranya Elsayed⁴, Mohammed Elsalanty⁴, Carlos M. Isales¹,⁶, Yutao Liu³, Mark W. Hamrick³,⁶, Krishnan M. Dhandapani²#, Sadanand Fulzele¹#.

¹Departments of Orthopaedic Surgery, Augusta University, Augusta, GA 30912
²Department of Neurosurgery, Augusta University, Augusta, GA 30912
³Cell Biology and Anatomy, Augusta University, Augusta, GA, 30912
⁴Departments of Pathology, Augusta University, Augusta, GA, 30912
⁵Department of Oral biology, Augusta University, Augusta, GA, 30912
⁶Institute of Regenerative and Reparative Medicine, Georgia Regents University, Augusta, GA, 30912

*Equal Contribution

Corresponding Authors (#)
#Sadanand Fulzele, PhD
Email: sfulzele@augusta.edu
Department of Orthopaedic Surgery
Augusta University, Augusta, GA, USA, Phone: 7067214850, Fax: 7067216002

#Krishnan Dhandapani, PhD
Email: kdhandapani@augusta.edu
Department of Neurosurgery,
Augusta University, Augusta, GA 30912, Phone: 7067218846, Fax: 7067216002

Running Title: Bone marrow derived EVs in TBI induced bone loss
Nonstandard Abbreviations

TBI: Traumatic brain injury
EVs: Extracellular vesicles
M-CSF: Macrophage colony-stimulating factor
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase
BMP2: Bone morphogenetic protein 2
RUNX2: Runt-related transcription factor 2
TRAP: Tartrate-resistant acid phosphatase
Abstract

Traumatic brain injury (TBI) is a major source of worldwide morbidity and mortality. Patients suffering from TBI exhibit a higher susceptibility to bone loss and an increased rate of bone fractures; however, the underlying mechanisms remain poorly defined. Herein, we observed significantly lower bone quality and elevated levels of inflammation in bone and bone marrow niche after controlled cortical impact-induced TBI in in-vivo CD-1 mice. Further, we identified dysregulated NFκB signaling, an established mediator of osteoclast differentiation and bone loss, within the bone marrow niche of TBI mice. Ex vivo studies revealed increased osteoclast differentiation in bone marrow-derived cells from TBI mice, as compared to sham injured mice. Finally, we found bone marrow derived extracellular vesicles (EVs) from TBI mice enhanced the colony forming ability and osteoclast differentiation efficacy of bone marrow cells and activated NFκB signaling genes in bone marrow-derived cells. Taken together, we provide evidence that TBI-induced inflammatory stress on bone and the bone marrow niche may activate NFκB leading to accelerated bone loss. Targeted inhibition of these signaling pathways may reverse TBI-induced bone loss and reduce fracture rates.

Key words: traumatic brain injury, bone loss, TBI, extracellular vesicles, EVs
Introduction

Traumatic brain injury (TBI) is a major cause of morbidity and mortality. TBI, which is defined as a blow or jolt to the head that produces permanent or temporary impairments in neurological function, affects individuals regardless of gender, ethnicity, age, and socio-economic status. Despite increased public awareness and improvements in safety measures, TBI contributes to nearly one-third of injury-related deaths [1-3] and millions of TBI survivors live with the long-term consequences of a prior TBI [4]. In contrast to other common neurological diseases, such as stroke and Alzheimer’s disease, TBI is more prevalent in younger populations, resulting in substantial loss of productive years and the need for life-long assisted care. This burdens families and health care systems that provide cognitive, emotional, physical, and psychological support for TBI survivors. Altogether, TBI places an annual $76.5 billion burden on society [5, 6].

In addition to the neurological consequences, TBI induces systemic immune changes that affect peripheral organs and worsen long-term quality of life [7-12]. Along these lines, TBI increases the risk of falls, fractures, osteopenia, and osteoporosis [13-21]. The increased risk for osteopenia and osteoporosis directly correlates with an elevated incidence of fractures and associated morbidity and mortality [22-24]. The mechanisms linking TBI with low bone mineral density and increased rate of fractures remain poorly defined and are likely multifactorial, with immobilization, epilepsy risk, anti-epileptic drugs, alcohol, and smoking as probable risk factors [13].

In this study, we investigated the effect of an isolated TBI on both macro and molecular bone changes. We hypothesized that inflammatory signaling in bone may represent a molecular link between TBI and increased bone resorption. In doing this, we isolated extracellular vesicles (EVs) from TBI bone marrow and showed their role in osteoclast differentiation. We also showed that bone marrow derived EVs following a TBI plays vital role in bone marrow niche.
molecular signaling. Delineating the root cause of low bone mineral density and bone loss in patients suffering from TBI can further guide treatment and possibly reduce one of the major causes of morbidity and mortality in the patient population.

Materials and Methods

Controlled cortical impact: The Institutional Animal Care and Use Committee (IACUC) at Augusta University approved all animal studies, in compliance with NIH guidelines. Adult CD-1 male mice (n=12-20) (Charles River, Wilmington, MA) were subjected to a sham injury or moderate controlled cortical impact (CCI), as detailed by our laboratory [25]. Briefly, mice were anesthetized using 3% isoflurane, placed in a stereotaxic frame, and a craniotomy was made in the right parietal bone midway between bregma and lambda with the medial edge 1 mm lateral to the midline, leaving the dura intact. Mice were impacted at 3 m/s with a 100 ms dwell time and 3 mm depression using a 3 mm diameter convex tip (PinPoint PCI3000 Precision Cortical Impactor, Hatteras Instruments, Cary, NC). Sham-operated mice underwent the identical surgical procedures, but were not impacted. The skin incision was closed and mice were allowed to recover in a clean, warm cage. Body temperature was maintained at 37 °C using a small animal temperature controller throughout all procedures (Kopf Instruments, Tujunga, CA, USA). Food and water were provided ad libitum.

Micro-computed Tomography Analyses (µCT): Micro-computed Tomography Analysis were performed (n=12-20) as per our published method [26]. For bone mineral density measurement and 3D morphometric analysis, 4% paraformaldehyde fixed femurs were scanned in a µCT system (Skyscan 1172; Skyscan, Aartlesaar, Belgium). Scanning was performed at an image pixel size of 14.59 μm. Reconstruction of the scanned images was done using a Skyscan
Nrecon program. The reconstructed datasets were loaded into Skyscan CT-analyzer software for measurement of bone mineral density and 3D morphometric parameters. Distal femur was selected as region of interest; the bone mineral density was measured in the region of interest after calibration with hydroxyl apatite phantoms of known density.

**Isolation of bone marrow cells for colony forming and osteoclast differentiation assay:**
The soft tissues were removed from the limbs with a sterile scalpel and the clean bones (n=6) were transferred into a petri dish on ice. Both ends of the long bone (epiphysis) of the femur were cut to expose the bone marrow. The PBS was used to flush out the bone marrow and collected in a 15 mL tube. The bone marrow cell suspension was centrifuged at 300 g for 5 min, the supernatant was used for EVs isolation and the pellet was resuspended in culture medium. Bone marrow cells were cultured overnight in 100 mm tissue culture dishes in alpha-MEM media (5% heat inactivated FBS, 25 units/mL penicillin/streptomycin, and 400 mM L-Glutamine). After 24hrs, non-adherent cell were collected, counted and re-plated in 24-well plates at 2x10³ cells/cm². Colony forming assay was performed by treating cells with alpha-MEM media (5% heat inactivated fetal bovine serum, 25 units/mL penicillin/streptomycin, and 400 mM L-Glutamine) containing 50 ng/mL M-CSF. For osteoclast differentiation cells were cultured in presence of 30 ng/mL macrophage colony-stimulating factor (M-CSF) and 50 ng/mL of RANKL for 4–6 days. The colony forming assay were stained with crystal violet and osteoclastogenesis cultures were stained for TRAP activity assay (Sigma; 387-A).

**Tartrate-resistant acid phosphatase staining:** Media was discarded from 24 cell culture plates and cells were washed twice with PBS and fixed as per manufactures protocol (tartrate of the Leukocyte Acid Phosphatase Assay kit, Sigma) for 30 min. After fixing, cells were washed twice with PBS, and then incubated with TRAP staining solution containing a mixture of Fast
Garnet GBC, sodium nitrite, naphtol AS-BI phosphoric acid, acetate, and tartrate of the Leukocyte Acid Phosphatase Assay kit (Sigma) following the manufacturer’s instruction. TRAP-positive multinucleated cells were counted under a light microscope.

**Isolation of RNA, synthesis of cDNA, and real-time PCR:** Total RNA was isolated from the tibia of mice (n=6). For RNA isolation, the bone marrow cellular material was directly dissolved in Trizol whereas tibia bone particles were ground in liquid N2 with a pestle and mortar, and the powdered tissue was dissolved in Trizol. RNA was isolated using the Trizol method following manufacturer’s instructions, and the quality of the RNA preparations was monitored by absorbance at 260 and 280 nm (Helios-Gamma, Thermo Spectronic, Rochester, NY). The RNA was reverse-transcribed into complementary deoxyribonucleic acid (cDNA) using iScript reagents from Bio-Rad on a programmable thermal cycler (PCR-Sprint, Thermo Electron, Milford, MA). 50 ng of cDNA was amplified in each real-time PCR using a Bio-Rad iCycler, ABgene reagents (Fisher scientific, Pittsburgh, PA) using appropriate primers (Table 1). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control for normalization.

**Extracellular vesicles isolation from bone marrow:** EVs were isolated using our published method [27, 28]. Briefly, complete bone marrow (n=6) content was dissolved into 500 uL PBS followed by centrifugation at 3000 RPM for 20 minutes to remove cell debris. The supematant was collected and again centrifuged at 3000 RPM for 30 minutes to remove the remaining cell debris. Supernatant was collected and then Total Exosome Isolation Reagent (Life Technologies, Carlsbad, CA) was used to isolate EVs as per manufacturer protocol. This protocol involved initial precipitation followed by centrifugation. After centrifugation, pellets were dissolved in 200 uL of phosphate-buffered saline (PBS) as EVs -enriched fractions. The particle
size and concentration of bone marrow derived EVs were measured using nanoparticle tracking analysis (NTA) with ZetaView (Particle Metrix, Meerbusch, Germany). Isolated EVs were used to perform functional studies.

**Extracellular vesicles treatment:** Bone marrow cells were cultured in 24-well plates and treated with sham and TBI bone marrow derived EVs (20 μg/ml) separately with 1% FBS (exosome free) media for 36 hrs. We pulled down BM derived-EVs from 8-10 sham and TBI separately to perform this experiment. IL-1, IL-6, TNFα, RELA and Birc3 gene expressions were performed using real time PCR ([Table 1](#)). Colony forming assay and osteoclast differentiation assay was performed as mentioned above in presence (20 μg/ml) or absent of EVs. The colony forming assay was stained with crystal violet and osteoclastogenesis cultures were stained for TRAP activity assay (Sigma; 387-A).

**Statistics:** GraphPad Prism 5 (La Jolla, CA) was utilized to perform pair-wise t-tests for microCT, real time PCR and staining quantification. A P value of <0.05 was considered significant.

**Results**

**Micro-computed tomography analysis of femur bone:** Micro-computed tomography (microCT) was used to measure bone mineral density (BMD), bone volume/total volume (BV/TV), trabecular thickness (TbTh) and trabecular separation (Tb.Sp) in femurs from sham or TBI injured mice. Our data showed significant decreases in bone mineral density ($p=0.0365$), bone volume ($p=0.0340$), trabecular thickness ($p=0.0521$) and trabecular number ($p=0.0630$) in...
TBI mice compared to the controls (Fig. 2). Furthermore, we found a trend toward increased ($p=0.058$) trabecular separation in TBI mice.

**Increased inflammation and decreased bone markers at 8 weeks post-TBI:** Real time PCR of bone-related markers and inflammatory genes was performed in bone chips derived from sham or TBI-injured mice at 8 weeks post-injury (Fig. 3). All bone related genes showed down-regulation in TBI mice, as compared to sham injured mice. BMP2 ($p=0.05$) and RUNX2 ($p=0.001$) showed significant down-regulations in 8 week TBI bone whereas osteocalcin showed trend of down-regulation ($p=0.064$), as compared to sham (Fig. 2c). In parallel to these changes, we observed chronic bone inflammation, as evidenced by increased expression of IL-1 ($p=0.001$), IL-6 ($p=0.01$), and TNF-α ($p=0.001$) in 8 week TBI bones, as compared to sham (Fig. 3d-f).

**Elevated chronic inflammation and NFκB signaling genes in bone marrow after TBI:** As bone marrow produces hematopoietic and mesenchymal stem cells, we next performed real-time PCR on selected inflammatory and NFκB signaling genes in bone marrow. We found that both inflammatory and NFκB signaling genes were dysregulated following TBI (Fig. 4). Specifically, IL-1 was increased 3-fold ($p=0.001$) whereas TNF-α was up-regulated six-fold ($p=0.04$) after TBI, as compared to sham-operated mice. IL-6 showed the most profound up-regulation with a ten-fold increase, as compared to sham group. We also observed an increase NFκB signaling genes (Birc3 and RelA/p65 genes). Birc3 gene increased four-fold ($p=0.001$) whereas RelA/p65 exhibited a ten-fold increase after TBI ($p=0.001$).
TBI affects colony forming unit (CFU) efficiency and osteoclast differentiation of bone marrow cells: Colony forming cells are one of the important pre-osteoclast cells which differentiate into osteoclasts. Thus, we next hypothesized that the elevated level of bone loss observed by microCT after TBI was due to increased colony forming activity and osteoclast differentiation efficiency by bone marrow cells after TBI. To test this hypothesis, isolated bone marrow cells from sham or TBI mice were cultured in the presence of macrophage colony-stimulating factor (M-CSF) for CFU and osteoclast media for osteoclast differentiation. TBI-derived bone marrow cells exhibited significantly higher \( p=0.01 \) CFU and cell proliferation efficiency (Fig. 5b). The osteoclast differentiation assay also showed similar findings. We found that TBI derived bone marrow cells have significantly \( p=0.01 \) higher TRAP positive multinucleated cells compared to sham group (Fig. 5a).

Extracellular vesicle isolation and characterization: We isolated EVs from sham and TBI mice bone marrow using precipitation and centrifugation. Nanoparticle tracking analysis showed that vesicles isolated from bone marrow are in the ~100 nm diameter size range, consistent with the known size of EVs [27, 28]. We did not find any significant changes in size or concentration of bone marrow derived EVs of TBI (Fig.6).

EVs derived from TBI bone marrow enhance osteoclast differentiation of bone marrow cells: Our data suggests the increase in TRAP positive multinucleated cells formation in the TBI bone marrow cells is due to changes in bone marrow microenvironment. We hypothesized that increased osteoclast differentiation of TBI bone marrow cells are partially due to extracellular vesicles. To test this hypothesis, bone marrow cells from sham and TBI mice were cultured in the presence of EVs derived from sham or TBI bone marrow. We found that TBI derived EVs significantly affected colony forming units as well as osteoclast differentiation.
efficiency of normal bone marrow cells (Fig.7). Furthermore, EVs derived from sham bone marrow partially prevented colony forming units and osteoclast differentiation efficiency of TBI bone marrow cells (Fig.7b).

**TBI-derived EVs isolated from bone marrow regulate inflammatory and NFκB signaling:**
To gain further insight into the role of EVs in osteoclast differentiation, normal bone marrow cells were treated with EVs isolated from sham and TBI bone marrow. We found that EVs regulate inflammatory and NFκB signaling of bone marrow cells. Our results showed a significant increase in IL-1 (p=0.026) and TNF-α (p=0.042) in bone marrow cells. IL-6 (p=0.018) had the highest up-regulation compared to IL-1 and TNF-α. Furthermore, NFκB signaling genes Birc3 (p=0.0054) and RelA/p65 (p=0.0028) were significantly up-regulated compared to control (Fig.8).

**Discussion**
TBIs induce chronic, broad sequelae that reduce long-term quality of life. Clinical data suggest a strong correlation between TBI and dysfunctions in autonomic regulation, neuroendocrine function, and psychiatric stability [1, 5-8]. Moreover, recent studies suggest that increased fracture rate is another long-term consequence of TBI [13-21]. The combination of an increased fall risk and low bone mineral density post-TBI has been associated with increased fracture rates [1, 8-21, 7]. In this study, we used an established pre-clinical model of focal TBI in mice. We found that a single, isolated head injury decreased bone mineral density and increased bone loss. Furthermore, our data also demonstrated decline in bone markers such as BMP2, RUNX2 and osteocalcin in bone and elevated levels of pro-inflammatory cytokines in bone marrow niche/environment after TBI. It is well established that traumatic injury to the brain produces inflammatory responses in the bloodstream and peripheral organs [29]. Ours is the
first study to demonstrate elevated levels of pro-inflammatory cytokines in the bone marrow niche/environment. The systemic production of pro-inflammatory cytokines in the bone marrow, bloodstream, and peripheral organs may play a vital role in secondary complications of TBI. Recent TBI studies in mice have shown similar damaging inflammatory cascades outside the central nervous system such as in the bloodstream [30], liver [29], kidney [31] and other organs. Hayakata et al (2004) reported elevated levels of pro-inflammatory cytokines in serum in the acute setting of a TBI within the first six hours post injury [32].

In normal physiological conditions, there is a balance between the activity of bone resorbing cells (osteoclasts) and bone forming cells (osteoblasts); however, this homeostasis may be disrupted under pathological conditions, leading to bone loss. Consistent with our findings showing a reduction in bone mineral density and increased bone loss, our in vitro data suggest bone marrow hematopoietic cells derived from TBI mice enhanced osteoclast activity, as compared to bone marrow from sham-injured mice. Beyond the demonstration of elevated levels of osteoclast differentiation after TBI, bone marrow from TBI mice increased colony formation, suggesting TBI creates an ideal microenvironment for osteoclast differentiation. Although the precise mechanisms underlying these effects remain undefined, oxidative stress and inflammation contribute toward post-menopausal and age-dependent bone loss [37, 38]. In particular, bone resorption and differentiation of osteoclast precursors to mature cells is regulated by the pro-inflammatory transcription factors, NFκB, and RANKL [40, 41]. Of note, we reported increased chronic inflammatory activation, involving the mobilization of bone marrow derived immune cells, within both blood and brain following a TBI [25, 33-36]. Consistent with these findings, the key NFκB genes, RelA/p65 and Birc3, were dysregulated in the bone marrow niche after TBI. Moreover, Vaira et al (2008) reported that RelA/p65 promotes osteoclast differentiation by blocking RANKL induced apoptosis whereas knockdown of RelA in the hematopoietic compartment blocked osteoclastogenic response to RANKL and protected
against arthritis-induced osteolysis [39]. Thus, TBI may create a chronic, pro-inflammatory environment within the bone marrow that contributes to progressive bone loss.

Different cell types within the bone marrow cavity communicate via the release of extracellular vesicles (EVs), which are ~100 nm diameter packaged vesicles containing specific proteins, lipids, factors, and/or genetic material. Recent studies suggested that bone marrow- and blood-derived exosomes regulate osteoblastic and osteoclastic differentiation in various musculoskeletal disease models [44-46]. As we similarly demonstrated that human synovial fluid-derived EVs play vital role in the pathophysiology of osteoarthritis [27], we herein explored whether EVs contribute to osteoclast differentiation efficiency after TBI. To answer this important question, we cultured bone marrow hematopoietic cells derived from sham-injured mice in the presence of bone marrow derived EVs from TBI mice. Interestingly, bone marrow derived EVs from TBI mice increased both osteoclast differentiation and colony forming cells in sham-derived bone marrow cells. Furthermore, we demonstrated that sham bone marrow derived EVs partially prevented osteoclast differentiation efficiency of TBI bone marrow cells. Moreover, bone marrow derived EVs isolated from TBI mice elevated pro-inflammatory cytokines and dysregulated NFκB signaling genes in bone marrow cells. Our findings in the context of TBI are in line with a report showing EVs derived from various body fluids, including amniotic fluid, liver cirrhosis ascites, and malignant ascites of ovarian cancer patients, activate inflammatory cytokines in monocyctic cells via NF-κB signaling [47].

Our well-established, pre-clinical TBI model produces a highly reproducible focal TBI; however, clinical TBI is a heterogeneous injury that may not be perfectly mimicked by any single rodent model. Thus, confirmation of our findings using other TBI models, such as lateral fluid percussion, and higher order species (e.g. porcine models) may be warranted prior to clinical translation. Our model used herein also produces a moderate-severe injury; thus, it would be interesting to determine whether similar effects are observed on bone density after a single
and/or repetitive mild TBI. These later studies may have direct relevance to athletes in contact sports and military personnel that are at risk of TBI. A potential caveat is the use of young, otherwise healthy male mice. While necessary to limit the scope of this proof of concept study, our studies do not consider the potential influence of common comorbidities that may influence bone physiology, including age and sex. Furthermore, we only assessed EVs effects in in-vitro cultures of bone marrow cell differentiation to osteoclasts. Further studies are needed to determine whether TBI derived exosomes affect the osteogenic differentiation ability of mesenchymal stromal cells. In addition, we did not elucidate which cargo (protein, miRNA) of exosomes is directly responsible for the increased pro-inflammatory cytokine production and osteoclast differentiation. Future studies are needed to investigate the EVs cargo and their role in TBI-induced bone loss.

Taken together, our study raises the interesting possibility that TBI fosters a chronic pro-inflammatory state within the bone marrow niche, culminating in increased bone resorption. Future work by our group will elucidate the source of EVs in bone marrow to determine whether EVs are locally released or transported from the injury site. We also will identify the cargo of TBI-derived EVs to further advance therapeutic development and the clinical translation of targeted therapies to prevent bone loss after TBI.

**Acknowledgments**: This work was supported by a grant from the National Institutes on Aging P01 AG 036675 to SF, MWH, and CS. KMD was supported by NIH grant (NS097825).

**Competing financial and non-financial interests**: The authors declare no competing financial and non-financial interests.
**Authors’ contributions:** Conceptualization, KD and SF; Formal analysis, KV, TF, ME, CI, MH, KD and SF; Funding acquisition, CI, MH, KD and SF; Investigation, KV and MB; Methodology, QS, KV, MB, AK, BM, RK, HK, MED, TF, RE, YL and SF; Resources, ME, CI and MH; Software, ME; Validation, KV, RE and ME; Writing – original draft, QS and SF; Writing – review & editing, QS and KD.

**References:**


Figure legends
**Figure. 1.** Representative cresyl violet-stained coronal brain sections from sham and TBI mice at 48 hours.

**Figure. 2.** Effects of TBI on bone structural quality of femur measured by micro-computed tomography (μCT). BMD, bone volume, tubercular thickness, and tubercular number were significantly decreased whereas tubercular separation was increased in the femurs of 8-week TBI mice compared to Sham. Results are means ± SD (n =12-20). *Significant p-value 0.05

**Figure. 3.** Dysregulation of bone markers and inflammatory genes in TBI bone. TBI animals showed decreased mRNA expression of a) BMP2, b) RUNX-2 and c) osteocalcin and increased expression of (d) IL-1, (e) IL-6 and (f) TNF-α in 8-week TBI bones. After reverse transcription of total RNA, cDNA was amplified by quantitative real-time PCR. Data for each sample were normalized with GAPDH mRNA represented as the fold change in expression compared to sham mouse. Results are means ± SD (n = 6). *Significant p-value<0.05 determined by paired t-test.

**Figure. 4.** Elevated level of inflammatory and NFkB signaling genes in TBI bone marrow. TBI mice showed increased mRNA expression of inflammatory genes (a) IL-1, b) IL-6, c) TNF-α and NFkB signaling genes (d), Birc3 (e) RelA/p65 in 8-week TBI bone marrow. After reverse transcription of total RNA, cDNA was amplified by quantitative real-time PCR. Data for each sample were normalized with GAPDH mRNA represented as the fold change in expression compared to sham mouse. Results are means ± SD (n = 6). *Significant p-value<0.05 determined by paired t-test.

**Figure. 5.** Effect of TBI on osteoclast differentiation and colony forming unit (CFU) on bone marrow cells. (a) Mouse primary bone marrow cells were cultured with RANKL (100 ng/ml) and M-CSF (30 ng/ml) for 4 days followed by TRAP staining. After TRAP staining, TRAP+...
multinuclear cells (TRAP+ MNCs) with more than three nuclei were scored as osteoclasts. (b) Colony forming assay was performed, stained with crystal violet, and colonies were counted. *P<0.05 and **P<0.01 compared with vehicle-treated control.

**Figure 6.** Characterization of TBI bone marrow derived EVs. (a) Particle size distribution is consistent with size range of EVs (average size 100 nm), measured by ZetaView® Particle Tracking Analyzer. No significant change in (b) particle size and (c) concentration in TBI and sham bone marrow derived EVs (n = 6).

**Figure.** 7. Effect of bone marrow derived EVs from TBI on colony forming unit (CFU) and osteoclast differentiation of bone marrow cells. (a) Colony forming assay were performed with M-CSF (30 ng/ml) in the presence or absence of sham/TBI derived EVs for 4 days, stained with crystal violet staining, and colonies were counted. (b) Mouse primary bone marrow cells were cultured with RANKL (100 ng/ml) and M-CSF (30 ng/ml) in the presence or absence of sham/TBI derived EVs for 6 days followed by TRAP staining. After TRAP staining, TRAP+ multinuclear cells (TRAP+ MNCs) with more than three nuclei were scored as osteoclasts.

**Figure.** 8. TBI derived bone marrow EVs regulate inflammatory and NFkB signaling gene expression. Bone marrow cells treated with sham and TBI derived EVs at concentrations of 20 µg/ml for 36hrs followed by RT-PCR, a) IL-1 b) IL-6II c) TNF-a, d) RelA/p65 and Birc3  
(n=6  
*P<.05)
Fig. 1
Fig. 4

(a) IL-1

(b) IL-6

(c) TNF-α

(d) Birc3

(e) RELA
Fig. 5

a) Osteoclast differentiation

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>TBI</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRAP+ Cells/Field</td>
<td>**</td>
<td>**</td>
</tr>
</tbody>
</table>

b) CFU assay

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>TBI</th>
</tr>
</thead>
<tbody>
<tr>
<td>CFU</td>
<td>**</td>
<td>**</td>
</tr>
</tbody>
</table>
Fig. 6

a) Graph showing size distribution of EVs.

b) Bar chart comparing EVs particle size between SHAM and TBI.

c) Bar chart comparing EVs concentration between SHAM and TBI.
Fig. 8

- **IL-1β**
  - Sham DXs: 1.0
  - TBI DXs: 2.8
- **IL-6**
  - Sham DXs: 1.0
  - TBI DXs: 2.6
- **TNF-α**
  - Sham DXs: 1.0
  - TBI DXs: 2.0

- **RELA**
  - Sham DXs: 1.0
  - TBI DXs: 2.5
- **Birc3**
  - Sham DXs: 1.0
  - TBI DXs: 2.5